All In Biotech

Drug Trial Radar · NCT03461146

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

24

Actual

Start

Mar 5, 2018

Primary completion

Dec 3, 2018

Study completion Dec 17, 2018

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Mar 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.

Conditions

  • Anemia; Hemodialysis Dependent Chronic Kidney Disease

Interventions

  • MT-6548Drug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hb Level of Week 20 and Week 24Time frame: Up to Week 24
  2. Hb Level at Each Assessment Time PointTime frame: Up to Week 24
  3. Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment PeriodTime frame: Up to Week 24
  4. Time to Reach the Target Hb RangeTime frame: Up to Week 24
  5. Rate of Increase in Hb LevelTime frame: Up to Week 6

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Research site

    Aichi, Japan

  • Research site

    Chiba, Japan

  • Research site

    Fukushima, Japan

  • Research site

    Gunma, Japan

  • Research site

    Hokkaido, Japan

  • Research site

    Hyōgo, Japan

  • Research site

    Ibaraki, Japan

  • Research site

    Kagoshima, Japan

  • Research site

    Nagano, Japan

  • Research site

    Okayama, Japan

  • Research site

    Okinawa, Japan

  • Research site

    Osaka, Japan

  • Research site

    Saitama, Japan

  • Research site

    Shiga, Japan

  • Research site

    Shizuoka, Japan

  • Research site

    Yamagata, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.